Radiotherapy is generally only used in advanced kidney cancer for the treatment of metastases in a select number of cases. However, the use of stereotactic ablative radiotherapy (SABR) offers promise for the treatment of metastatic spread of kidney cancer to different locations in the body. An expert in the field discussed the present situation with respect to SABR and what future trials may show at the 15th International Kidney Cancer Symposium, held on 4-5 November 2016 in Miami, Florida.

Read more here